Esophageal and Gastric Varices
Conditions
Brief summary
Many physicians suggest repeating EVL every 1-2 weeks until esophageal varices are obliterated to prevent variceal rebleeding， however, the evidences supporting the efficacy of EVL intervals of 1-2 weeks are insufficient.This randomized controlled study was conducted in order to compare the long-term results of EVL when performed at two different results from monthly and bi-weekly treatments.
Detailed description
Endoscopic variceal ligation (EVL) is a safe and simple procedure now being used on a widening scale. A lot of patients who undergo endoscopic treatment for esophageal varices eventually require additional treatment for recurrent varices. Many physicians suggest repeating EVL every 1-2 weeks until esophageal varices are obliterated to prevent variceal rebleeding， however, the evidences supporting the efficacy of EVL intervals of 1-2 weeks are insufficient.This randomized controlled study was conducted in order to compare the long-term results of EVL when performed at two different results from monthly and bi-weekly treatments.
Interventions
PROCEDUREmonthly Endoscopic Variceal Ligation (EVL)
Patients in this group will underwent endoscopic variceal ligation monthly.
PROCEDUREbi-weekly Endoscopic Variceal Ligation (EVL)
Patients in this group will underwent endoscopic variceal ligation bi-weekly.
Sponsors
West China Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. acute or recent bleeding from esophageal varices; 2. portal hypertension caused by cirrhosis; 3. age between 18 and 80 yr.
Exclusion criteria
1. history of endoscopic, pharmacological, interventional or surgical treatment of esophageal varices; 2. presence of liver failure with a serum total bilirubin concentration greater than 3 mg/dL; 3. presence of hepatocellular carcinoma or other malignancy; 4. an association with a cerebral vascular accident, uremia, acute coronary syndrome, or other severe illness; 5. history of gastric variceal bleeding; 6. encephalopathy of stage II or worse; 7. failure to control initial variceal bleeding; 8. death within 48 h of admission; 9. refusal to participate in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| variceal rebleeding rate | 2 years |
Secondary
| Measure | Time frame |
|---|---|
| gastrointestinal rebleeding rate | 2 years |
| variceal obliteration rate | 2 years |
| number of sessions required to abstain variceal obliteration | 2 years |
| adverse events | 2 years |
| mortality | 2 years |
Countries
China
Contacts
Primary ContactXUEFENG LUO, MD
Outcome results
None listed